Gene · 8242
Papers1,955
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 1,955
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Epigenetic reprogramming shapes the cellular landscape of schwannoma. | Nat Commun | 2024 | 38216587 | PubTator, text mining | PubMed |
| The human Y and inactive X chromosomes similarly modulate autosomal gene expression. | Cell Genom | 2024 | 38190107 | PubTator, text mining | PubMed |
| Comprehensive analysis of a tryptophan metabolism-related model in the prognostic prediction and immune status for clear cell renal carcinoma. | Eur J Med Res | 2024 | 38183155 | PubTator, text mining | PubMed |
| Notch activation defines immune-suppressive subsets of ccRCCs with unfavorable benefits from immunotherapy over VEGFR/mTOR inhibitors. | iScience | 2024 | 38179060 | PubTator, text mining | PubMed |
| KDM5B predicts temozolomide-resistant subclones in glioblastoma. | iScience | 2024 | 38174322 | PubTator, text mining | PubMed |
| Dysregulated ANLN reveals immune cell landscape and promotes carcinogenesis by regulating the PI3K/Akt/mTOR pathway in clear cell renal cell carcinoma. | Heliyon | 2024 | 38173514 | PubTator, text mining | PubMed |
| A study on genotypes and phenotypes of short stature caused by epigenetic modification gene variants. | Eur J Pediatr | 2024 | 38170291 | PubTator, text mining | PubMed |
| A novel prognostic predictor of immune microenvironment and therapeutic response in clear cell renal cell carcinoma based on angiogenesis-immune-related gene signature. | Heliyon | 2024 | 38170124 | PubTator, text mining | PubMed |
| Targeting the PHF8/YY1 axis suppresses cancer cell growth through modulation of ROS. | Proc Natl Acad Sci U S A | 2024 | 38165927 | PubTator, text mining | PubMed |
| De novo variants underlying monogenic syndromes with intellectual disability in a neurodevelopmental cohort from India. | Eur J Hum Genet | 2024 | 38114583 | PubTator, text mining | PubMed |
| Mutational landscape of head and neck cancer and cervical cancer in Chinese and Western population. | Head Neck | 2024 | 38111234 | PubTator, text mining | PubMed |
| Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts. | J Mol Med (Berl) | 2024 | 37978056 | PubTator, text mining | PubMed |
| Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma. | J Pathol Clin Res | 2024 | 37974379 | PubTator, text mining | PubMed |
| Computational analysis of protein-protein interactions of cancer drivers in renal cell carcinoma. | FEBS Open Bio | 2024 | 37964489 | PubTator, text mining | PubMed |
| Histone demethylases in neurodevelopment and neurodegenerative diseases. | Int J Neurosci | 2024 | 37902510 | PubTator, text mining | PubMed |
| Episignatures in practice: independent evaluation of published episignatures for the molecular diagnostics of ten neurodevelopmental disorders. | Eur J Hum Genet | 2024 | 37872275 | PubTator, text mining | PubMed |
| Histone demethylase Kdm5c regulates osteogenesis and bone formation via PI3K/Akt/HIF1α and Wnt/β-catenin signaling pathways. | Genes Dis | 2024 | 37588198 | PubTator, text mining | PubMed |
| A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial. | Cancer Res Treat | 2024 | 37475136 | PubTator, text mining | PubMed |
| Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. | Mol Cell Biochem | 2024 | 37016182 | PubTator, text mining | PubMed |
| Five years of experience in the Epigenetics and Chromatin Clinic: what have we learned and where do we go from here? | Hum Genet | 2024 | 36952035 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8242/papers?page=7